海利生物(603718.SH):擬投資杭州樹辰生物 其為研發並商業化新冠肺炎重組腺病毒疫苗項目而成立
格隆匯 8 月 11日丨海利生物(603718.SH)公佈,公司此次投資的杭州樹辰生物技術有限公司(“標的公司”)目前尚未開展經營活動,在相關業務開展的人才、技術儲備上還有待構建和培育;同時,研發、生產涉及的相關實驗室及場地也尚待建設,因此都需要一定的時間週期,存在較大的不確定性。
公司之前未曾涉及人用疫苗的直接研發、生產和銷售,目前主營業務仍為獸用疫苗的研發、生產、銷售以及全資子公司上海捷門生物技術有限公司從事的醫用體外診斷試劑研究、開發、生產和銷售業務。
公司通過召開第三屆董事會第十八次會議,審議通過了《關於公司對外投資的議案》,公司通過增資的方式投資人民幣3400萬元,持有標的公司40%的股權併成為標的公司控股股東。
標的公司主要是為研發並商業化新冠肺炎重組腺病毒疫苗項目而成立的項目公司,目前已分別與浙江大學(浙江大學醫學院附屬第一醫院傳染病診治國家重點實驗室)、浙江樹人大學簽訂《技術諮詢合同》、《技術開發合同書》,基於近期世界主要流行新冠肺炎病毒流行毒株的生物信息學分析和其他研究發現,進行新冠肺炎重組腺病毒疫苗的毒種篩選研發和藥效學研究(動物免疫原性試驗),並同其他合作方共同進行腺病毒載體體系的放大生產的工藝研究,近期將在動物數據進一步成熟後啟動毒理學和其他關鍵藥效學試驗和臨牀研究。上述合作產生的有關研發成果和專利等知識產權將歸屬於標的公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.